Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Stereotactic Radiotherapy With Irinotecan in Colorectal Cancer Liver/Lung Metastasis
NCT01220063Phase 2Completed
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Oct 2007
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Objective Tumor Response Rate of Irradiated Lesions at 48 months. Started Oct 2007; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01220063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220063.